Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TRAIL and malignant glioma.

Christine J Hawkins1

  • 1Murdoch Children's Research Institute Department of Haematology and Oncology, Royal Children's Hospital Department of Paediatrics, University of Melbourne Parkville, Victoria 3052, Australia.

Vitamins and Hormones
|April 28, 2004
PubMed
Summary

Some cancers are treatable with chemotherapy and radiation, but malignant glioma is resistant. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for treating resistant cancers like glioma by triggering apoptosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.

BMC cancer·2024
Same author

Molecular basis for nuclear accumulation and targeting of the inhibitor of apoptosis BIRC2.

Nature structural & molecular biology·2023
Same author

Reconstitution of human pyroptotic cell death in Saccharomyces cerevisiae.

Scientific reports·2023
Same author

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.

International journal of molecular sciences·2022
Same author

Establishment and Characterisation of Metastatic Extraskeletal Ewing Sarcoma Mouse Models.

In vivo (Athens, Greece)·2021
Same author

The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.

Clinical & experimental metastasis·2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Conventional cancer therapies like chemotherapy and radiation activate intrinsic apoptosis pathways.
  • Malignant glioma and other cancers exhibit resistance to current treatments due to a block in apoptosis.
  • The extrinsic apoptosis pathway offers an alternative route to induce cancer cell death.

Purpose of the Study:

  • To review the efficacy of TNF-related apoptosis-inducing ligand (TRAIL) in inducing apoptosis in malignant glioma cells.
  • To explore the potential of TRAIL-based agents for treating glioma.

Main Methods:

  • Discussion of the extrinsic apoptosis pathway triggered by TNF-alpha family death ligands.
  • Review of TRAIL's mechanism of action and its selective toxicity.

Related Experiment Videos

  • Analysis of existing research on TRAIL and its analogs in cancer treatment.

    • Main Results:

    • TRAIL and its analogs demonstrate potential in selectively inducing apoptosis in cancer cells resistant to conventional therapies.
    • TRAIL exhibits negligible toxicity to normal cells compared to other death ligands like TNF-alpha and FasL.
    • Malignant glioma cells may be susceptible to apoptosis induction via the TRAIL pathway.

    Conclusions:

    • TRAIL represents a promising therapeutic candidate for overcoming resistance in malignant glioma.
    • Targeting the extrinsic apoptosis pathway with TRAIL-based agents could offer a novel strategy for glioma treatment.
    • Further clinical investigation of TRAIL-based therapies is warranted for glioma patients.